

Adiponectin and leptin in pregnancy induced hypertension, a matter of weight

La adiponectina y leptina en la hipertensión inducida por el embarazo, una cuestión de peso

Hugo Mendieta Zerón¹

¹MD, MSc, PhD. Medical Sciences Research Center (CICMED), Autonomous University of the State of Mexico (UAEMex); Ciprés Grupo Médico (CGM), Asociación Científica Latina (ASCILA).

Recibido: 16/04/2012

Aceptado: 20/06/2012

51

Resumen

Niveles bajos circulantes de adiponectina en conjunto con niveles altos de leptina han sido identificados como factores de riesgo noveles para diabetes y preeclampsia. Aun en presencia de embarazo normal, mujeres son sobrepeso embarazadas tienen concentraciones bajas de adiponectina en comparación con aquellas normopeso. Más aún, niveles bajos de adiponectina en el primero trimestre es un factor de riesgo independiente para el desarrollo de diabetes mellitus gestacional (GDM). Concentraciones circulantes de leptina durante el embarazo, se elevan 2 o 3 veces por encima de lo observado en mujeres no gestantes, y se elevan aún más en preeclampsia. Desafortunadamente, no hay existen puntos de referencia reproducibles y validados para leptina mensuales en el embarazo. Es necesario estandarizar (si es necesario) los posibles valores de referencia de estas adipokinas como marcadores de desarrollo de preeclampsia.

Palabras Claves: adiponectina; diabetes gestacional; leptina; preeclampsia; diabetes tipo 2; peso.

Abstract

Low circulating levels of adiponectin and increased leptin have emerged as novel diabetic and preeclamptic risk factors. Even in the presence of a normal pregnancy, overweight pregnant women have a lower adiponectin concentration than those with a normal weight. Moreover, low concentrations of adiponectin in the first or early second trimester is an independent risk factor for the development of Gestational Diabetes Mellitus (GDM). Circulating leptin concentrations during pregnancy are elevated 2 to 3 fold above that observed in nonpregnant women, leptin concentrations are further elevated in preeclampsia. Unfortunately until now, there are not reproducible and widely accepted references for adiponectin and leptin for every month of pregnancy. So it is necessary to standardize the methodologies and propose possible values (if useful) of these adipokines as prognosis markers to develop preeclampsia.

Keywords: adiponectin; gestational diabetes; leptin; preeclampsia; type 2 diabetes mellitus; weight

Introduction

Maternal hormonal and metabolic factors related to the placenta, adipose tissue and the growth hormone axis are associated with the variation in insulin sensitivity seen during normal human pregnancy¹. Obesity-mediated factors potentially may be relevant to the pathophysiologic relationship between weight gain and preeclampsia. Recently, low circulating levels of adiponectin and increased leptin and C-reactive protein (CRP) have emerged as novel diabetic risk factors; although their relevance to gestational diabetes mellitus (GDM) and subsequent diabetes has not been characterized. In the past decade, a growing body of evidence has identified two pathologic se-

quelae of obesity that may link adiposity to diabetic risk: increased serum leptin and low circulating levels of the insulin-sensitizing protein adiponectin^{2,3}.

Adiponectin

Adiponectin, an adipokine produced abundantly by adipocytes, is the most abundant gene (AMP1) product of adipose tissue⁴, and circulates at high concentrations in the plasma⁵. This adipokine consists of three heterogeneous species of multimers that can exert differential biological effects: a) low-molecular-weight (LMW) trimers, b) medium-molecular-weight (MMW) hexamers and c) high-molecular weight (HMW) isoform⁶⁻⁸. Unlike other

adipokines, adiponectin concentrations are negatively correlated with adiposity⁹, suggesting that adipose tissue exerts a negative feedback on adiponectin production and/or secretion. Adiponectin is postulated to play a role in the modulation of glucose and lipid metabolism in insulin-sensitive tissues^{10,11}, besides antiinflammatory properties¹², thus providing a mechanistic molecular basis for the association between an excess fat depot and obesity-related complication including type 2 diabetes mellitus (2DM). Moreover, recent findings indicate that adiponectin has antiatherogenic, anti-diabetic and angiogenic properties¹³.

Data regarding circulating maternal adiponectin multimers concentrations in human pregnancy are limited¹⁴⁻¹⁶. Normal pregnancy is associated with alterations in maternal circulating adiponectin¹⁷⁻¹⁹ and with changes in the relative distribution of its isoforms^{20,21}. In addition, even in the presence of a normal pregnancy, overweight pregnant women have a lower adiponectin concentration than those with a normal weight²². Moreover, low concentrations of adiponectin in the first or early second trimester is an independent risk factor for the development of GDM. Indeed, maternal adiponectin concentration < 6.4 µg/ml at 13 weeks of gestation is associated with a 4.6-fold increased risk to develop GDM later in pregnancy²³, suggesting a causal relationship between low circulating adiponectin and GDM²⁴⁻²⁶. Collectively, a growing body of evidence points to a key role of adiponectin in the pathophysiology of both 2DM and GDM.

This hormone has been implicated in both the physiological adaptation to normal pregnancy and in obstetrical complications²⁷. Circulating adiponectin concentrations decrease in insulin-resistant states, including 2DM^{11,28}. Hypoadiponectinemia in pregnancy predicts postpartum insulin resistance, beta-cell dysfunction, and fasting glycaemia²⁹. Low adiponectin levels in intra uterine growth restriction (IUGR) infants may actually predict the subsequent development of visceral fat and insulin resistance³⁰.

Previous studies have demonstrated that, in pregnancy, women with GDM exhibit evidence of sub-clinical inflammation and dysregulation of adipokines, including low circulating levels of both adiponectin and its HMW multimeric form^{21,23}. In fact, both sub-clinical inflammation and hypoadiponectinemia may be chronic defects in this patient population, as increased CRP and low adiponectin in the first trimester have each been shown to independently predict the subsequent development of GDM later in pregnancy²³. The significance of the current findings rests in the potential implications that a relationship between antepartum adiponectin and future 2DM could hold for diabetic risk stratification and modification. Specifically, it follows from these data that antepartum adiponectin concentration may provide a means of stratifying women with GDM with respect to their future risk of 2DM. Ideally, this information could help to target postpartum surveillance efforts to those women at the highest risk of de-

veloping diabetes. The availability of this predictor at the time of diagnosis in pregnancy may be particularly important, in light of the well-recognized sub-optimal rates of postpartum metabolic follow-up in women with GDM³¹. Secondly, the current data also suggest that chronic hypoadiponectinemia could provide a therapeutic target for risk modification in this patient population. In this respect, it is of interest to note that thiazolidinedione therapy, which has been shown to preserve beta-cell function and significantly reduce the risk of developing 2DM in women with a history of GDM³² is also known to increase adiponectin levels. It thus emerges that a pathophysiologic relationship between hypoadiponectinemia and diabetic risk following GDM could hold important clinical implications.

Leptin

The central source of leptin is the adipose tissue, although it can also be produced in other sites, including the placenta^{33,34}, in fact, microarray experiments have demonstrated a higher expression profile of placental leptin gene in preeclamptic women than in normal pregnancies³⁵.

Leptin mainly acts by binding to specific central and peripheral receptors in the hypothalamus, adipose tissue, liver, and pancreatic beta-cells³⁶. Leptin stimulates a negative energy balance by increasing energy expenditure and reducing food intake³⁷. Rodents and humans lacking leptin or functional leptin receptors develop severe obesity and hyperphagia³⁸. However, endogenous hyperleptinemia fails to stimulate body weight loss in obese individuals, suggesting that a state of leptin resistance is linked to the development of obesity³⁹.

Leptin receptor is a possible new candidate for the endocrine control of human pregnancy⁴⁰. To maintain the increased energy intake in the face of increased adiposity and rising leptin levels, pregnant females become resistant to the central anorectic actions of leptin. In rats, pregnancy-induced leptin resistance is characterised by elevated neuropeptide Y (NPY) and reduced pro-opiomelanocortin (POMC) expression in the arcuate nucleus (Arc), reduced leptin receptor mRNA levels and suppression of leptin-induced phosphorylated signal transducer and activator of transcription-3 protein (STAT-3) in the ventromedial hypothalamic nucleus, as well as a loss of anorectic responses to both leptin and alpha-melanocyte-stimulating hormone (α-MSH). This leptin-resistance may also cause central insulin resistance and an altered peripheral glucose homeostasis⁴¹. Even more, findings from a Chinese group suggest that the Lys656Asn polymorphism, a functional variant in the LEPR, and high leptin levels are risk factors for preeclampsia⁴².

Leptin is produced in both maternal and fetal adipose tissues and the placenta^{43,44}, while its receptors are abundant in the uterine endometrium, trophoblast, and the fetus⁴⁵. Fetal adipose tissue is an important source of leptin and fetal leptin levels are strongly related to birth weight and fetal adiposity⁴⁶⁻⁴⁸. The role of leptin in placental function

has not been fully elucidated but it is supposed to play a role in the regulation of placental amino acid transport by activation of the JAK-STAT pathway⁴⁹.

A possible leptin's involvement in pathophysiological adaptations that define the foetal growth potential can be supported⁵⁰, because this adipokine seems to be a critical factor for overall fetal development^{42,51}. For example, maternal first trimester serum leptin demonstrates a significant negative association with neonatal weight in preeclamptic pregnancies and to a lesser extent in normotensive pregnancies.

Furthermore, a strong association between neonatal leptin levels, bone mineral content and estimated bone density has been confirmed, supporting a role for leptin in the process of fetal bone remodelling⁵². Leptin may play a role in the control of substrate utilization and in the maintenance and functional characteristics of fat mass before birth, producing permanent changes concerning adiposity and body composition in adult life.

Circulating leptin concentrations during pregnancy are elevated 2 to 3 fold above that observed in nonpregnant women, leptin concentrations are further elevated in the pregnancy complication preeclampsia and are lower in pregnancies complicated by IUGR^{53,54}. However, clinical and experimental trials have not yet clarified the definite role of leptin in the pathophysiologic mechanisms of high-risk pregnancies^{55,56}. Previous studies have demonstrated that plasma leptin concentrations are increased significantly during the third trimester of preeclamptic pregnancies in contrast to normal pregnancies^{57,58}. Other studies have documented that plasma leptin levels are elevated even before preeclampsia had become clinically evident⁵⁹⁻⁶¹. Amongst the groups involved in the study of leptin and preeclampsia our team has showed that a value above 40 ng/ml in the

third trimester of pregnancy seems to be a good predictor for preeclampsia⁶². However, the exact mechanism underlying the increased plasma leptin levels in preeclampsia and the functional role of leptin in the development of hypertension need to be further clarified⁶³. How the knowledge that leptin is associated to hypertension could be applied in clinical practice is still a matter of debate.

Impaired Glucose Tolerance (IGT) during pregnancy is associated with leptin gene DNA methylation adaptations with potential functional impacts. These epigenetic changes provide novel mechanisms that could contribute to explaining the detrimental health effects associated with fetal programming, such as long-term increased risk of developing obesity and 2DM⁶⁴.

Until now, there are several papers relating to leptin and adiponectin in pregnancy but we have found heterogeneous results (Table 1). So it is necessary to standardize the methodologies and propose possible values (if useful) as prognosis markers to develop preeclampsia.

Summary

Maternal adipokines are related to several diseases. Being more specific, adiponectin has antiatherogenic, anti-diabetic and angiogenic properties but in pregnancy overweight women have a lower adiponectin concentration than those with a normal weight. In relation to leptin, its concentrations during pregnancy are elevated 2 to 3 fold above the values observed in nonpregnant women, and are further elevated in preeclampsia. Our group has reported that in Mexican morbid obese women, a value higher than 40 ng/ml in the second trimester, is highly predictive of preeclampsia. To our best knowledge there isn't any drug targeting at leptin receptor to explore new antihypertensive options.

Table 1. Comparative values reported for leptin and adiponectin in pregnancy*

	Month																			
	3			4			7			8			9							
	Normal	IGT	Overweight	Normal	IGT	GDM	Normal	IGT	GDM	Normal	Obesity	Severe preeclampsia	Normal	IGT	GDM	Overweight	Obesity	Mild preeclampsia	Severe preeclampsia	
Adiponectin (µg/ml)																				
Retnakaran R ²⁹							8	7	7							6.019		3.022		5.207
Mazaki-Tovi S ¹⁸																				
Nien JK ^{27,65}										8.48	6.946	9.632								
Nakatsukasa H ⁶⁶																13				30
Gao XL ⁶⁷				9.18	6.88	5.06	5.7	4.5	3											
Kyriakakou M ⁶⁸																11.8				
Leptin (ng/ml)																				
Retnakaran R ²⁹							32.9	35.7	35.8											
Bouchard L ⁶⁴	28.9	25.8											44.1	25.7						
Nakatsukasa H ⁶⁶													20					21		
Sucak A ⁶³													16.3						30.6	31.7
Kim KH ⁶⁹	9.87		17.8										15.73			20.93				
Gao XL ⁶⁷				4.89	9.61	12.79	8.88	15.11	22.64											
Kyriakakou M ⁶⁸													20.4							

IGT: impaired glucose test, GDM: gestational diabetes mellitus.

* If necessary, values have been transformed into the same units, µg/ml for adiponectin and ng/ml for leptin.

References

- 1 McIntyre HD, Chang AM, Callaway LK, et al. Hormonal and metabolic factors associated with variations in insulin sensitivity in human pregnancy. *Diabetes Care*. 2010; 33:356-360.
- 2 Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? *Diabetologia*. 1998; 41:1241-1248.
- 3 Retnakaran R, Hanley AJ, Raif N, et al. Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. *Diabetes Care*. 2004; 27:799-800.
- 4 Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. *J Biol Chem*. 1996; 271:10697-10703.
- 5 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab*. 2004; 89:2548-2556.
- 6 Aso Y, Yamamoto R, Wakabayashi S, et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. *Diabetes*. 2006; 55:1954-1960.
- 7 Mazaki-Tovi S, Romero R, Vaisbuch E, et al. Maternal serum adiponectin multimers in gestational diabetes. *J Perinat Med*. 2009; 37:637-650.
- 8 Tsao TS, Tomas E, Murrey HE, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. *J Biol Chem*. 2003; 278:50810-50817.
- 9 Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun*. 1999; 257:79-83.
- 10 Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. *Nat Med*. 2001; 7:947-953.
- 11 Schondorf T, Maiworm A, Emmison N, et al. Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. *Clin Lab*. 2005; 51:489-494.
- 12 Schulze MB, Rimm EB, Shai I, et al. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. *Diabetes Care*. 2004; 27:1680-1687.
- 13 Fantuzzi G. Adipose tissue, adipokines, and inflammation. *J Allergy Clin Immunol*. 2005; 115:911-919.
- 14 Catalano PM, Hoegh M, Miniium J, et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. *Diabetologia*. 2006; 49:1677-1685.
- 15 Fasshauer M, Waldeyer T, Seeger J, et al. Circulating high-molecular-weight adiponectin is upregulated in preeclampsia and is related to insulin sensitivity and renal function. *Eur J Endocrinol*. 2008; 158:197-201.
- 16 Takemura Y, Osuga Y, Koga K, et al. Selective increase in high molecular weight adiponectin concentration in serum of women with preeclampsia. *J Reprod Immunol*. 2007; 73:60-65.
- 17 Mazaki-Tovi S, Kanety H, Pariente C, et al. Determining the source of fetal adiponectin. *J Reprod Med*. 2007; 52:774-778.
- 18 Mazaki-Tovi S, Kanety H, Pariente C, et al. Maternal serum adiponectin levels during human pregnancy. *J Perinatol*. 2007; 27:77-81.
- 19 Mazaki-Tovi S, Kanety H, Sivan E. Adiponectin and human pregnancy. *Curr Diab Rep*. 2005; 5:278-281.
- 20 Mazaki-Tovi S, Romero R, Vaisbuch E, et al. Maternal serum adiponectin multimers in preeclampsia. *J Perinat Med*. 2009; 37:349-363.
- 21 Retnakaran R, Connelly PW, Maguire G, et al. Decreased high-molecular-weight adiponectin in gestational diabetes: implications for the pathophysiology of Type 2 diabetes. *Diabet Med*. 2007; 24:245-252.
- 22 Girouard J, Giguere Y, Moutquin JM, et al. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. *Hypertension*. 2007; 49:1056-1062.
- 23 Williams MA, Qiu C, Muy-Rivera M, et al. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. *J Clin Endocrinol Metab*. 2004; 89:2306-2311.
- 24 Ategbro JM, Grissa O, Yessoufou A, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. *J Clin Endocrinol Metab*. 2006; 91:4137-4143.
- 25 Kinalski M, Telejko B, Kuzmicki M, et al. Tumor necrosis factor alpha system and plasma adiponectin concentration in women with gestational diabetes. *Horm Metab Res*. 2005; 37:450-454.
- 26 Tsai PJ, Yu CH, Hsu SP, et al. Maternal plasma adiponectin concentrations at 24 to 31 weeks of gestation: negative association with gestational diabetes mellitus. *Nutrition*. 2005; 21:1095-1099.
- 27 Nien JK, Mazaki-Tovi S, Romero R, et al. Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. *J Perinat Med*. 2007; 35:522-531.
- 28 Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab*. 2001; 86:1930-1935.
- 29 Retnakaran R, Qi Y, Connelly PW, et al. Low adiponectin concentration during pregnancy predicts postpartum insulin resistance, beta cell dysfunction and fasting glycaemia. *Diabetologia*. 2010; 53:268-276.
- 30 Cianfarani S, Martinez C, Maiorana A, et al. Adiponectin levels are reduced in children born small for gestational age and are inversely related to postnatal catch-up growth. *J Clin Endocrinol Metab*. 2004; 89:1346-1351.
- 31 Clark HD, Graham ID, Karovitch A, et al. Do postal reminders increase postpartum screening of diabetes mellitus in women with gestational diabetes mellitus? A randomized controlled trial. *Am J Obstet Gynecol*. 2009; 200:634-637.
- 32 Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. *Diabetes*. 2002; 51:2796-2803.
- 33 Hoggard N, Haggarty P, Thomas L, et al. Leptin expression in placental and fetal tissues: does leptin have a functional role? *Biochem Soc Trans*. 2001; 29:57-63.
- 34 Christou H, Serdy S, Mantzoros CS. Leptin in relation to growth and developmental processes in the fetus. *Semin Reprod Med*. 2002; 20:123-130.
- 35 Kang JH, Song H, Yoon JA, et al. Preeclampsia leads to dysregulation of various signaling pathways in placenta. *J Hypertens*. 2011; 29:928-936.
- 36 Auwerx J, Staels B. Leptin. *Lancet*. 1998; 351:737-742.
- 37 Ahima RS, Flier JS. Leptin. *Annu Rev Physiol*. 2000; 62:413-437.
- 38 Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature*. 1997; 387:903-908.

- 39 Krechowec SO, Vickers M, Gertler A, et al. Prenatal influences on leptin sensitivity and susceptibility to diet-induced obesity. *J Endocrinol.* 2006; 189:355-363.
- 40 Toth B, Fischl A, Scholz C, et al. Insulin and leptin receptors as possible new candidates for endocrine control in normal and disturbed human pregnancy. *Mol Hum Reprod.* 2009; 15:231-239.
- 41 Ladyman SR, Augustine RA, Grattan DR. Hormone interactions regulating energy balance during pregnancy. *J Neuroendocrinol.* 2010; 22:805-817.
- 42 Wang S, Qiao FY, Feng L. High leptin level and leptin receptor Lys656Asn variant are risk factors for preeclampsia. *Genet Mol Res.* 2013;12:2416-2422.
- 43 Alexe DM, Syridou G, Petridou ET. Determinants of early life leptin levels and later life degenerative outcomes. *Clin Med Res.* 2006; 4:326-335.
- 44 Mostyn A, Keisler DH, Webb R, et al. The role of leptin in the transition from fetus to neonate. *Proc Nutr Soc.* 2001; 60:187-194.
- 45 Hassink SG, de LE, Sheslow DV, et al. Placental leptin: an important new growth factor in intrauterine and neonatal development? *Pediatrics.* 1997; 100:E1.
- 46 Clapp JF, III, Kiess W. Cord blood leptin reflects fetal fat mass. *J Soc Gynecol Investig.* 1998; 5:300-303.
- 47 Geary M, Herschkovitz R, Pringle PJ, et al. Ontogeny of serum leptin concentrations in the human. *Clin Endocrinol (Oxf).* 1999; 51:189-192.
- 48 Geary M, Pringle PJ, Persaud M, et al. Leptin concentrations in maternal serum and cord blood: relationship to maternal anthropometry and fetal growth. *Br J Obstet Gynaecol.* 1999; 106:1054-1060.
- 49 von Versen-Hoyneck F, Rajakumar A, Parrott MS, et al. Leptin affects system A amino acid transport activity in the human placenta: evidence for STAT3 dependent mechanisms. *Placenta.* 2009; 30:361-367.
- 50 Papastefanou I, Samolis S, Panagopoulos P, et al. Correlation between maternal first trimester plasma leptin levels and birth weight among normotensive and preeclamptic women. *J Matern Fetal Neonatal Med.* 2010; 23:1435-1443.
- 51 Reitman ML, Bi S, Marcus-Samuels B, et al. Leptin and its role in pregnancy and fetal development--an overview. *Biochem Soc Trans.* 2001; 29:68-72.
- 52 Javid MK, Godfrey KM, Taylor P, et al. Umbilical cord leptin predicts neonatal bone mass. *Calcif Tissue Int.* 2005; 76:341-347.
- 53 Catov JM, Patrick TE, Powers RW, et al. Maternal leptin across pregnancy in women with small-for-gestational-age infants. *Am J Obstet Gynecol.* 2007; 196:558.
- 54 Yildiz L, Avci B, Ingec M. Umbilical cord and maternal blood leptin concentrations in intrauterine growth retardation. *Clin Chem Lab Med.* 2002; 40:1114-1117.
- 55 Henson MC, Castracane VD. Leptin in pregnancy: an update. *Biol Reprod.* 2006; 74:218-229.
- 56 Lepercq J, Catalano P, Hauguel de MS. [Leptin in pregnancy: facts, questions and future]. *Gynecol Obstet Fertil.* 2007; 35:89-95.
- 57 Hendler I, Blackwell SC, Mehta SH, et al. The levels of leptin, adiponectin, and resistin in normal weight, overweight, and obese pregnant women with and without preeclampsia. *Am J Obstet Gynecol.* 2005; 193:979-983.
- 58 Ozkan S, Erel CT, Madazli R, et al. Serum leptin levels in hypertensive disorder of pregnancy. *Eur J Obstet Gynecol Reprod Biol.* 2005; 120:158-163.
- 59 Chan TF, Su JH, Chung YF, et al. Elevated amniotic fluid leptin levels in pregnant women who are destined to develop preeclampsia. *Acta Obstet Gynecol Scand.* 2006; 85:171-174.
- 60 Iftikhar U, Khoja A, Mehjabeen, et al. Evaluation of serum leptin levels during normal pregnancy and in pre-eclampsia. *J Ayub Med Coll Abbottabad.* 2008; 20:137-140.
- 61 Anim-Nyame N, Sooranna SR, Steer PJ, et al. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and pre-eclampsia. *Hum Reprod.* 2000; 15:2033-2036.
- 62 Mendieta Zerón H, García Solorio VJ, Nava Díaz PM, et al. Hyperleptinemia as a prognostic factor for preeclampsia: a cohort study. *Acta Medica (Hradec Kralove).* 2012;55:165-171.
- 63 Sucak A, Kanat-Pektas M, Gungor T, et al. Leptin levels and antihypertensive treatment in preeclampsia. *Singapore Med J.* 2010; 51:39-43.
- 64 Bouchard L, Thibault S, Guay SP, et al. Leptin gene epigenetic adaptation to impaired glucose metabolism during pregnancy. *Diabetes Care.* 2010; 33:2436-2441.
- 65 Nien JK, Mazaki-Tovi S, Romero R, et al. Adiponectin in severe preeclampsia. *J Perinat Med.* 2007; 35:503-512.
- 66 Nakatsukasa H, Masuyama H, Takamoto N, et al. Circulating leptin and angiogenic factors in preeclampsia patients. *Endocr J.* 2008; 55:565-573.
- 67 Gao XL, Yang HX, Zhao Y. Variations of tumor necrosis factor-alpha, leptin and adiponectin in mid-trimester of gestational diabetes mellitus. *Chin Med J (Engl).* 2008; 121:701-705.
- 68 Kyriakakou M, Malamitsi-Puchner A, Militsi H, et al. Leptin and adiponectin concentrations in intrauterine growth restricted and appropriate for gestational age fetuses, neonates, and their mothers. *Eur J Endocrinol.* 2008; 158:343-348.
- 69 Kim KH, Kim YJ, Lee S, et al. Evaluation of plasma leptin levels & BMI as predictor of postpartum weight retention. *Indian J Med Res.* 2008; 128:595-600.

Esta Revista se publica bajo el auspicio del
Consejo de Desarrollo Científico y Humanístico,
 UCV

Aumenta la visibilidad de tus investigaciones
 Ingresa a saber.ucv.ve

